TEVA — Teva Pharmaceutical Industries Limited American Depositary Shares stock price and chart

TEVA

Teva Pharmaceutical Industries Limited American Depositary SharesStock · Health Care

$38.98-0.54%

as of market close, Sep 18, 2026

☾ AH — —

PeersMRNALLYUNHJNJMRKTMO

Technical analysis2

Overlay lines0

Addendum charts0

VolumeDDDDD

20162019202120242026

10.015.020.025.030.035.040.045.050.055.00200.0M$38.98

2026-09-18

Price$38.98

MA20$34.66

MA50$28.99

Vol22.9M

What would $1,000 invested in TEVA be worth today? →

TEVA returns: By year · By month · By week · Trailing

Key stats

Price data

Price: $38.98
Change YTD: +24.90%
Next earnings: Nov 4, 2026
Market cap: 45.4B2017-06 33.8B2026-09 45.4B+34.4% over the window
Enterprise value: 63.3B
Shares outstanding: 1.2B2016-12 961M2026-06 1.2B+21.3% over the window
52W low: $18.21
52W high: $39.70
From 52W high: -1.81%
From 52W low: +114.06%
52W range: 97%
Beta: 0.86

Volume

Rel volume: 1.08×
30D volume: 5.1M
30D $ vol: 189.1M

Fundamentals

Sales (ttm): 17.3B2016-12 21.9B2026-06 17.3B-20.9% over the window
Sales/share: $14.862016-12 $22.792026-06 $14.86-34.8% over the window
EPS (ttm): $0.602016-12 $0.072026-06 $0.60+762.0% over the window
FCF (ttm): 1.3B2016-12 3B2026-06 1.3B-54.9% over the window
FCF/share: $1.162016-12 $3.112026-06 $1.16-62.8% over the window
Book value/share: $6.652016-12 $34.692026-06 $6.65-80.8% over the window
Net margin: 4.08%2016-12 1.5%2026-06 4.1%+171.5% over the window
ROE: 9.11%2016-12 1.0%2026-06 9.1%+822.7% over the window
ROA: 1.77%2016-12 0.4%2026-06 1.8%+401.0% over the window
Debt / equity: 2.15×2016-12 0.982026-06 2.15+120.1% over the window
Current ratio: 0.882016-12 0.932026-06 0.88-5.6% over the window

Growth (CAGR, ttm) · 10Y

Sales: +4.13%2025-06-30 → 2026-06-3016.6B → 17.3B (+4.1% total)+4.86%2023-06-30 → 2026-06-3015B → 17.3B (+15.3% total)+1.19%2021-06-30 → 2026-06-3016.3B → 17.3B (+6.1% total)-1.20%2015-12-31 → 2026-06-3019.7B → 17.3B (-11.9% total)
Net income: n/an/an/a-7.43%2015-12-31 → 2026-06-301.6B → 706M (-55.5% total)
FCF: +51.50%2025-06-30 → 2026-06-30890M → 1.3B (+51.5% total)+4.74%2023-06-30 → 2026-06-301.2B → 1.3B (+14.9% total)n/a-11.34%2015-12-31 → 2026-06-304.8B → 1.3B (-71.7% total)
Shares: +1.58%2025-06-30 → 2026-06-301.1B → 1.2B (+1.6% total)+1.31%2023-06-30 → 2026-06-301.1B → 1.2B (+4.0% total)+1.11%2021-06-30 → 2026-06-301.1B → 1.2B (+5.7% total)+2.89%2015-12-31 → 2026-06-30864M → 1.2B (+34.9% total)

Per-share growth (CAGR, ttm) · 10Y

EPS: n/an/an/a-9.98%2015-12-31 → 2026-06-30$1.82 → $0.60 (-66.8% total)
Sales/share: +2.51%2025-06-30 → 2026-06-30$14.50 → $14.86 (+2.5% total)+3.50%2023-06-30 → 2026-06-30$13.40 → $14.86 (+10.9% total)+0.08%2021-06-30 → 2026-06-30$14.80 → $14.86 (+0.4% total)-3.97%2015-12-31 → 2026-06-30$22.75 → $14.86 (-34.7% total)
FCF/share: +49.14%2025-06-30 → 2026-06-30$0.78 → $1.16 (+49.1% total)+3.39%2023-06-30 → 2026-06-30$1.05 → $1.16 (+10.5% total)n/a-13.83%2015-12-31 → 2026-06-30$5.52 → $1.16 (-79.0% total)
Book value/share: +11.80%2025-06-30 → 2026-06-30$5.95 → $6.65 (+11.8% total)+1.87%2023-06-30 → 2026-06-30$6.29 → $6.65 (+5.7% total)-6.60%2021-06-30 → 2026-06-30$9.36 → $6.65 (-28.9% total)-14.50%2015-12-31 → 2026-06-30$34.45 → $6.65 (-80.7% total)
Price: +111.38%2025-09-18 → 2026-09-18$18.45 → $38.98 (+111.3% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+54.63%2023-09-18 → 2026-09-18$10.54 → $38.98 (+269.8% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.+34.08%2021-09-17 → 2026-09-18$8.99 → $38.98 (+333.6% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.-2.79%2016-09-16 → 2026-09-18$51.74 → $38.98 (-24.7% total)Price appreciation from split-adjusted daily closes, excluding dividends; endpoints are exact trading-day anniversaries of the latest close.
Total return: +111.38%2025-09-18 → 2026-09-18$18.45 → $38.98 (+111.3% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+54.63%2023-09-18 → 2026-09-18$10.54 → $38.98 (+269.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.+34.08%2021-09-17 → 2026-09-18$8.99 → $38.98 (+333.6% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.-2.43%2016-09-16 → 2026-09-18$49.87 → $38.98 (-21.8% total)Total return with dividends reinvested (adjusted daily closes); endpoints are exact trading-day anniversaries of the latest close. The gap against the Price row is the dividend contribution.

Fundamentals end at the last reported quarter; price and total return end at the latest close.

Valuation

P/E (ttm)Price ÷ TTM diluted EPS. Net income carries everything below the operating line, including one-off gains. Negative when the trailing year lost money.: 64.6×2016-09 25.282026-09 64.34+154.5% over the window
P/OI (ttm)Price ÷ TTM operating income. Excludes the below-the-line items that make P/E jump — mark-to-market gains, settlements, tax true-ups.: 28.3×2017-06 15.682026-09 28.34+80.7% over the window
Fwd P/E: 12.5×
P/S (ttm)Market cap ÷ TTM revenue.: 2.6×2017-06 1.442026-09 2.62+81.9% over the window
P/B (mrq)Market cap ÷ stockholders' equity at the most recent quarter end.: 5.9×2017-06 1.012026-09 5.86+478.1% over the window
P/FCF (ttm)Market cap ÷ TTM free cash flow (operating cash flow − capex).: 33.7×2017-06 11.302026-09 33.70+198.1% over the window
EV/EBITDA (fy): 24.4×
EV/Sales (ttm): 3.7×
FCF yield (ttm)TTM free cash flow ÷ market cap — the inverse of P/FCF.: 2.97%2017-12 7.0%2026-06 3.4%-51.3% over the window
Buyback yield (realized, 1y)1 − shares_at(2026-06-30) ÷ shares_at(2025-06-30) = 1 − 1.17B ÷ 1.15B. Point-in-time share counts from the company's own SEC filings (the same count at both ends), published only when the cash flow statement shows repurchases inside that window. A falling price can't inflate it; negative means net dilution.: -1.58%
Shareholder yield (realized, 1y)Buyback leg + dividend leg: shares retired over the year (-1.58%) + dividends paid over that year ($0) ÷ market_cap_at(2025-06-30) ($19.2B). Both legs are measured against the start of the window, so a payout can't shrink its own denominator.: -1.58%
Buyback yield (cash, ttm)Buybacks net of issuance over the trailing twelve months ($0) ÷ today's market cap ($45.4B). Dollars SPENT over what the company is worth NOW — a stock that fell after buying reads high.: 0.00%2017-12 0.0%2026-06 0.0%
Shareholder yield (cash, ttm)(TTM buybacks net of issuance $0 + TTM dividends $0) ÷ today's market cap ($45.4B). Same caveat as the cash buyback yield.: 0.00%2017-12 4.7%2026-06 0.0%-100.0% over the window

Vs own 10Y history

P/E: 72nd
P/OI: 73rd
P/S: 100th
P/B: 100th
P/FCF: 81st

Bar = where today’s multiple sits in TEVA’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).

Performance · price return · as of 2026-09-18

-0.54%

+5.10%

+6.56%

+23.82%

YTD

+24.90%

+111.27%

+333.59%

Financial statements

Open full TEVA financials →

Loading financial statements…

Ticker	Name	1M	1D
NVS	Novartis AG	-9.18%	-0.39%
NVO	Novo Nordisk A/S	-5.40%	+0.12%
SNY	Sanofi ADS	-5.54%	-1.53%
GSK	GSK plc American Depositary Shares (Each representing two Ordinary Shares)	-1.82%	-1.65%
ARGX	argenx SE American Depositary Shares	-0.27%	-0.55%
TAK	Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	+4.76%	-0.73%
NTRA	Natera Inc.	+18.51%	+0.84%
RVMD	Revolution Medicines Inc.	-11.60%	-3.04%

Teva Pharmaceutical Industries Limited American Depositary Shares (TEVA) trades at $38.98 with a live price and an interactive chart covering 44+ years of daily price history, plus key valuation metrics. ChartRow also publishes TEVA’s financial statements free — annual and quarterly income statement, balance sheet, and cash flow straight from SEC filings, with P/E and valuation history and dividend data. See full TEVA financial statements →

TEVA — Teva Pharmaceutical Industries Limited American Depositary Shares price, chart and key statistics